Caricamento...
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
BACKGROUND. Sorafenib has proven survival benefits in patients with advanced hepatocellular carcinoma (HCC). The viability of continuing sorafenib at a higher dosage in patients who experienced radiologic disease progression was investigated. METHODS. Patients who experienced disease progression whi...
Salvato in:
| Autori principali: | , , , , , , , , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
AlphaMed Press
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3639524/ https://ncbi.nlm.nih.gov/pubmed/23580239 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0221 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|